RxDoctor Payments DataLook up a doctor →

Alan Zausner Skarbnik, MD

Hematology · Charlotte, NCNPI 1366754954

Payments from drug & device makers

$9,760,104in general payments, 2019–2025

Across 1,150 payments — averaging $8487.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$2.5M
  • Acerta Pharma LLC$1.7M
  • Bristol Myers Squibb$1.5M
  • Hoffmann-la Roche Limited$915K
  • Genentech, Inc.$731K
  • AbbVie$625K
  • plus $1.8M from 37 others
$250,580in research payments, 2019–2025

Across 16 payments — averaging $15,661 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$241K
  • AstraZeneca$5K
  • F. Hoffmann-la Roche AG$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,760,104 in reported general payments places this provider in the 95th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$106,639
Medicare patients
230
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →